RxDoctor Payments DataLook up a doctor →

Samir Patel, MD

Pain Medicine · Baton Rouge, LANPI 1356526917

Payments from drug & device makers

$11,291in general payments, 2019–2025

Across 572 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$2K
  • Nevro Corp.$1K
  • Amgen$821
  • Collegium Pharmaceutical, Inc.$683
  • AbbVie$556
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$11,291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,291 in reported general payments places this provider in the 80th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$270,485
Medicare patients
505
Services billed
4,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,327$73,645
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,698$63,757
RelistorMethylnaltrexone Bromide19$46,007
MovantikNaloxegol Oxalate86$38,862
Gabapentin2,446$25,867
NucyntaTapentadol Hcl14$22,933
Pregabalin992$15,574
Celecoxib704$11,411
GraliseGabapentin11$10,014
Oxycodone Hcl500$9,226
HorizantGabapentin Enacarbil11$7,826
Methocarbamol743$7,606
Cyclobenzaprine Hcl990$7,293
Tizanidine Hcl617$6,727
Diclofenac Sodium131$6,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$353$46,00719 claims
Redhill Biopharma Inc.Movantik$16$38,86286 claims
Collegium Pharmaceutical, Inc.Nucynta$683$22,93314 claims
Arbor Pharmaceuticals, Inc.Horizant$106$7,82611 claims
AbbVieSavella$556$5,04411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 97 pain medicine providers in Louisiana.

Other pain medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →